Pfizer: cheap on earnings, fully priced on cash

Every screener shows Pfizer at about 10 times earnings with a 6% dividend yield. The 2025 cash flow statement shows something else: $9.1 billion of free cash flow and $9.8 billion of dividends. Adjusted earnings were $18.4 billion that year. The dividend was paid out of the smaller number.

Part of that gap is temporary, and I give Pfizer credit for it below. Even after the credit, the shares at the October 12, 2026 close of $28.40 trade 10.5% above my triangulated Base value of $25.70, a downside of 9.5%. The Bear value of $18.42 is 35.1% below the price and the Bull value of $34.02 is 19.8% above it. Confidence is grade C (14/25), the required margin of safety (MOS) is 45%, and the maximum buy price is $14.14. My broker quoted $28.41 at midday on October 13, so the close is a fair reference.

Valuation route: Large pharmaceutical company in the middle of a patent cliff. Classification: Standard (3/12). Primary method: price to normalized free cash flow at a patent-cliff multiple, plus a risk-adjusted value for the obesity pipeline. Secondary method: six-year free cash flow model with a terminal value. Cross-check: P/E on 2027 consensus earnings per share. Values are present fair value estimates, not 12 month price targets. All figures are in US dollars.

What Pfizer is

Pfizer sells prescription medicines and vaccines worldwide: the blood thinner Eliquis (shared with Bristol Myers Squibb), the Vyndaqel family for a rare heart disease, the Prevnar pneumonia vaccines, cancer drugs such as Ibrance, Xtandi and the Seagen portfolio (Padcev, Adcetris, Tukysa), the migraine drug Nurtec and the COVID products Comirnaty and Paxlovid. Revenue was $62.6 billion in 2025. Twelve products sold more than $1 billion each and together made up 65% of revenue. Eliquis alone was 13%.

The company is in a squeeze between two clocks. The first is the loss of exclusivity (LOE) on several of those twelve products, which management says hits mostly from 2026 through 2028. A third-party account of the first-quarter 2026 call puts the annual revenue at stake at about $14 billion to $15 billion, down from about $17 billion before Pfizer settled the Vyndamax patent suits. I could not confirm that range in the transcript excerpts I read, so treat it as an estimate. The second clock is the replacement: launched and acquired products brought in $3.2 billion in the second quarter, up 18% operationally, and the company has bet up to $10 billion on Metsera ($7 billion in upfront cash, the rest in contingent payments) and a once-a-month obesity injection that it hopes to get approved in 2028.

Management's framing is precise. It says revenue should not fall more than 3% to 4% in 2028, that growth should return from 2029, and that it has "clear line of sight" to a risk-adjusted high single-digit revenue growth rate from 2028 to 2033. Risk-adjusted is doing a lot of work in that sentence. The obesity drug, the new cancer combinations and the oncology bispecific licensed from 3SBio all have to land for that rate to hold.

The latest quarter

The impairment is worth a second look. Pfizer recorded $4.4 billion of intangible impairments in the fourth quarter of 2025 and another $4.3 billion in the second quarter of 2026, the latter tied mainly to a Phase 3 lung cancer readout for a Seagen-derived drug. Adjusted earnings exclude both. They are non-cash today, but they are the accounting record of money already spent on acquisitions that will not earn what Pfizer paid for them.

Why adjusted earnings overstate the cash

Adjusted EPS is the number Pfizer guides to and the number screeners divide into the price. It excludes acquired-intangible amortization, restructuring charges, certain legal costs and impairments. Free cash flow (operating cash flow minus capital spending) catches what adjusted EPS leaves out, and for Pfizer it has been about half as large.

In 2025 adjusted EPS of $3.22 on about 5.71 billion shares came to $18.4 billion. Free cash flow was $9.1 billion, a conversion of 49%. Three things explain most of the gap, and they are not equally durable.

• A tax bill that has ended. Pfizer paid its $15 billion repatriation tax from the 2017 US tax reform in eight installments: $1.5 billion in 2024, $2.1 billion in 2025 and the final $2.6 billion in April 2026. From 2027 that drain is gone.
• Working capital. It absorbed $5.4 billion in 2025 and $3.5 billion in the first half of 2026, partly from COVID contracts paid in advance years ago that now turn into revenue with no new cash. The Comirnaty backlog was $2.0 billion at June 28, so this fades but does not vanish before 2028.
• Deals paid through operating cash flow. Upfront licensing payments count as research expense: $1.35 billion to 3SBio in 2025 and $650 million to Innovent in the third quarter of 2026. Restructuring cash for the cost programs also runs through here. I treat both as recurring, because Pfizer keeps doing them.

My normalized free cash flow adds back the repatriation tax and subtracts stock-based compensation (SBC, pay in shares), which is a real cost to owners. That gives $10.46 billion for 2024, $10.38 billion for 2025 and $12.64 billion for the last twelve months (my arithmetic). The trailing figure includes a $1.6 billion working capital release in the fourth quarter of 2025, so I use $11.0 billion as the 2026 starting point, or $1.92 a share.

Balance sheet, shares and capital allocation

Net debt is $51.5 billion: $63.2 billion of debt less $11.7 billion of cash and short-term investments. Management keeps gross leverage near its 2.7 times target and says it will stay "around current levels, or modestly higher" through the patent cliff. Goodwill and intangibles total $118.5 billion against equity of $85.2 billion, so tangible book value is negative. That is normal for a serial acquirer and not a solvency issue, but it means the balance sheet has little to offer if the acquired assets disappoint.

The share count is flat. Diluted shares were about 5.70 billion in 2024 and guidance assumes 5.74 billion for 2026. There have been no buybacks since a $2 billion program in 2022. The remaining authorization is $3.3 billion, and management says repurchases come back only after deleveraging. In 2025 Pfizer returned $9.8 billion as dividends, invested $10.4 billion in internal research and spent about $8.8 billion on deals, mainly Metsera and 3SBio. Business development capacity after Innovent is about $6 billion.

Primary valuation: price to normalized free cash flow

For large pharmaceutical companies my method uses a multiple of normalized free cash flow that depends on how much revenue faces generic competition. The bands are 8 to 11 times when more than 30% of revenue loses exclusivity within five years, 11 to 14 times for a balanced portfolio, and 14 to 18 times with a strong late-stage pipeline. Pfizer's exposure of about $14 billion to $15 billion is roughly 23% of revenue, so it sits at the low end of balanced. I apply the multiple to the average free cash flow from 2026 to 2028, the years the cliff hits, and add a separate risk-adjusted value for the obesity program because none of its cash shows up before 2028.

Revenue paths and margins are my estimates. The Base path is $61.5 billion in 2026 (guidance midpoint), $60.0 billion in 2027 and $59.0 billion in 2028, a 4% decline that matches the floor management describes. The Bear path falls to $55 billion by 2028 and the Bull path holds flat at $61.5 billion. Free cash flow here is after SBC and interest, so the multiple gives equity value directly, divided by 5.74 billion shares.

The obesity value uses risk-adjusted net present value: peak sales times the probability of success times a present value factor, less remaining development cost. In the Base: $5 billion of peak sales, a 55% chance of approval from Phase 3, a factor of 3.0 and $2.25 billion of remaining cost give $6.0 billion. The Bear uses $3 billion and 40% ($2.0 billion). The Bull uses $7 billion and 60% ($9.0 billion) and adds $3 billion for oncology readouts beyond what the multiple already assumes. All are my estimates. Pfizer agreed to pay up to $10 billion for Metsera, so my Base values the program at about 60% of the purchase price.

Sensitivity: value per share (including $6 billion pipeline value)

Only the corner of the grid, 14 times on $11.5 billion, reaches the price. That combination is a strong-pipeline multiple on free cash flow that does not fall through the cliff.

Secondary valuation: six-year free cash flow model

The multiple method compresses the recovery into one number. The cash flow model spells it out: explicit free cash flow for 2027 to 2032, then a terminal value growing at a fixed rate, all discounted to today. It is the only method here that gives full credit to management's post-2028 growth plan, which is why it lands higher.

The Base 2027 figure of $10.8 billion is slightly below my $11.0 billion starting point because Ibrance and Xtandi lose exclusivity in 2027, partly offset by the end of the repatriation tax. 2028 is the trough, when Eliquis goes generic in the US. From 2029 free cash flow grows 8%, 7% and 6% a year, roughly what a high single-digit revenue growth rate with stable margins would give. The secondary Base is $30.74, and 71% of it sits in the terminal value, so it leans heavily on the years after the cliff.

Sensitivity of the Base model: value per share

Earnings cross-check and growth diagnostics

I could not verify a long history of Pfizer's own valuation multiples from a source I trust, so the historical weight goes to a forward P/E cross-check. Third-party consensus for 2027 adjusted EPS, summed from quarterly estimates by 4 to 8 analysts, is $2.71. I use $2.50 in the Bear and $2.85 in the Bull (my estimates), at 9, 10 and 11 times, discounted one year at 9%. That gives $20.64, $24.90 and $28.76. Ten times is below the big pharma average on purpose, because Pfizer's adjusted earnings convert to cash at about half the rate of its peers' reported earnings.

The growth-adjusted check (PEG) is a diagnostic only. The forward P/E is 9.8 times the 2026 guidance midpoint of $2.90 and 10.5 times the 2027 consensus, which is 6.4% lower than this year. Earnings are expected to shrink, so a PEG ratio is not meaningful. Growth durability: normalizing, as COVID revenue falls toward a floor, then uncertain through the cliff. Cyclical distortion: low, because drug demand does not follow the economic cycle; the distortions here come from COVID and patent expiries. There is also an accounting basis mismatch: GAAP EPS was $1.36 in 2025 against adjusted EPS of $3.22.

The free cash flow growth quality check says the long-run growth rate is not meaningful either. Free cash flow fell from $29.87 billion in 2021 to $9.08 billion in 2025, a compound decline of 25.8% a year over four years, but 2021 was a pandemic peak, not a base. From 2024 to 2025 it fell 7.7%. Normalized, it was $10.46 billion, $10.38 billion and $12.64 billion over the last twelve months, on a share count that grew only 0.7% in total. Free cash flow yield is 5.6% on 2025 reported cash, 6.7% on the trailing figure and 6.7% on my $11.0 billion starting point. Distortion flags: working capital, tax timing, deal payments inside operating cash flow, and a large gap between accounting earnings and cash. Estimate reliability: low, because no free cash flow consensus is available. Stress test: cutting Base free cash flow by 20% gives a primary value of $18.61, and by 40% gives $14.22. Classification: normalizing, with the direction after 2028 uncertain. This check does not set fair value.

Valuation triangulation

The primary and secondary Base values differ by 28.8% measured against their midpoint, inside the 20% to 30% warning band. I lower the valuation robustness score and add 5 points to the margin of safety for it. The disagreement has a clear source: the multiple method assumes the cliff is roughly offset and nothing more, while the cash flow model gives full credit to growth from 2029. The P/E check sits 7.9% from the primary, but it rests on adjusted earnings, so it is the least conservative of the three in what it counts. I kept the 50/30/20 weights I use across this site.

What is the market already pricing in?

At $28.40 and 5.74 billion diluted shares, Pfizer's market value is $163.0 billion, or 14.8 times my normalized free cash flow of $11.0 billion. Enterprise value (market value plus net debt) is about $214.5 billion. At an 8.5% cost of equity, the price implies that $11.0 billion of free cash flow grows about 1.6% a year forever. Starting from the $10.5 billion average through the cliff, it implies 1.9%. At 9% the figures are 2.1% and 2.4%.

That is not a distressed price. It assumes the patent cliff is fully bridged and that modest growth follows, which is almost exactly my Base cash flow model at a 9% discount rate ($28.50). In other words, the market is already paying for management's recovery plan, discounted at a normal rate for a large drug company. A buyer at $28.40 needs the obesity program and the oncology launches to deliver roughly as promised. A buyer who wants a margin of safety for the chance that they do not has to wait.

Bear, base and bull scenarios

I assign no probabilities. The Bear case is not a collapse. Pfizer still earns $8.5 billion to $10 billion of free cash flow a year in it, and the dividend would need cutting only if management chose to protect leverage instead. The skew is unfavorable: 19.8% of upside to the Bull against 35.1% of downside to the Bear.

How the buy price is set

A Confidence C score carries a base margin of safety of 35% to 50%, and I start at 35%. I add 5 points for pricing and pipeline risk (Medicare negotiated prices, the US most-favored-nation pricing agreement and a Phase 3 obesity program with a 2028 target) and 5 points for the 28.8% divergence between the two main methods. Leverage of 2.7 times is moderate, so no leverage modifier applies, and no positive modifier applies either. The required MOS is 45%, and the maximum buy price is $25.70 times 0.55, or $14.14.

That is below the Bear value of $18.42, which happens when the method's uncertainty is wider than the scenarios themselves. The margin of safety is meant to cover the case where my scenarios are wrong, not only the case where the Bear arrives. For context, $1.72 of dividends on a $14.14 purchase price would be a 12.2% yield.

Dividend

Pfizer pays $0.43 a quarter, or $1.72 a year, a yield of 6.1% at $28.40. The fourth-quarter payment on December 7, 2026 will be its 352nd consecutive quarterly dividend. The rate has been $0.43 since early 2025, and the last cut was in 2009, from $0.32 to $0.16 a quarter, during the Wyeth acquisition. The annual cash cost is about $9.8 billion.

The dividend takes 59% of the adjusted EPS midpoint but nearly all of the free cash flow. Management has repeatedly said it will maintain the dividend and grow it over time. I take that at face value for 2026 to 2028, because the cash covers it in my Base. What the cash does not cover is a raise, buybacks and deleveraging at the same time, so the yield is the return, not the beginning of a growing one.

Reasons to own PFE

• A cash drain just ended. The last $2.6 billion repatriation tax installment was paid in April 2026. All else equal, 2027 operating cash flow is $2.6 billion higher than 2026.
• The replacement portfolio is growing fast. Launched and acquired products grew 18% operationally in the second quarter and brought in $10.2 billion in 2025. Tukysa won US approval as a first-line maintenance treatment for HER2-positive breast cancer on October 7, 2026.
• Vyndamax got three more years. Settlements with three generic makers extend effective US exclusivity to June 1, 2031. Pfizer had expected a significant US decline from 2029, and now expects stable revenue from 2028 to mid-2031, subject to other litigation.
• Cost cuts are large and specific. Net savings of about $9.7 billion through 2029 across the cost realignment and manufacturing programs, including $2.5 billion of additional savings announced in August for 2027 to 2029.
• The obesity bet is moving. Ten Phase 3 studies of the monthly injection are planned or running in 2026, and in September the CEO said they were essentially fully recruited, in record time. A switch study tests whether patients on weekly drugs can move to monthly maintenance.

What could go wrong?

• Thesis breaker: the cliff is steeper than the launches. Eliquis (13% of 2025 revenue), Ibrance, Xtandi and Xeljanz face generic competition through 2028. If launched products slow before 2028, free cash flow falls below my Bear path.
• US pricing. Medicare negotiated prices apply to Eliquis from 2026, and Ibrance and Xtandi are in the next round. Pfizer has also signed a voluntary agreement with the US government on lower prices and the TrumpRx.gov platform. Each lowers net price on products already in decline.
• Acquisition returns. Two quarters out of the last three carried more than $4 billion of impairments each. Seagen cost $43 billion in 2023, and the $10 billion Metsera price assumes a monthly drug that has not finished Phase 3.
• Cash conversion. Adjusted earnings have converted to free cash flow at about 50%. If that does not improve after the tax and COVID effects fade, my $11.0 billion starting point is too high.
• Leverage through the trough. Management expects leverage to stay at 2.7 times or modestly higher during the cliff. Another large deal would push it up while the dividend absorbs almost all free cash flow.
• COVID revenue. Guidance for COVID products was cut from $5 billion to $4 billion this year, and Paxlovid demand follows infection levels Pfizer cannot forecast.

Management execution

Dr. Albert Bourla is chairman and chief executive. Chief financial officer Dave Denton is leaving for another opportunity and Cecile Guegan is interim CFO, so the finance chair is open in the middle of the cliff. On delivery, Pfizer says it has beaten consensus adjusted EPS in all of the last 10 quarters and revenue in 9 of them, and it has raised the cost savings target several times. On capital allocation, the record is weaker. The COVID windfall went largely into acquisitions, Seagen-related assets have been written down twice in a year, and the obesity program had to be bought after internal candidates were dropped. Assessment: 12/20, good at running the business, mixed at buying the next one.

Stock Analyza scorecard

Revenue grew about 8% a year from 2020 to 2025 on paper, but that path runs through the pandemic peak and back down, so I give it no points. Return on invested capital was about 9% over the last twelve months on reported figures, a modest spread over the cost of capital. The patent cliff takes the durability points. Character change: changing, from a company living off COVID cash to one living off a few aging blockbusters while it buys its next portfolio. I handle that through a cliff multiple and a higher margin of safety rather than a lower verdict.

Business quality is 47/100: moat and pricing power 11/20, return versus cost of capital 7/20, balance sheet 7/15, earnings and cash quality 7/15, growth and runway 7/15, management and capital allocation 5/10, dilution and governance 3/5 (flat share count, but the chairman and CEO roles are combined). The valuation score is 32/100: discount to Base 12/40, protection against the Bear case 4/20, agreement between methods 6/15, market-implied expectations 4/10 and data and model quality 3/5. Historical valuation is not scored because I could not verify the data, so the remaining 29 of 90 points are rescaled to 100.

Confidence score

The financial data come from Pfizer's filings, earnings releases and calls, and they reconcile. Predictability is low through 2028 because of the cliff and a binary obesity readout. Robustness is lowered by the 28.8% method divergence and by the 71% terminal share in the cash flow model. Accounting gets 3 because adjusted results exclude large recurring items and impairments come back often.

What I would watch from here

Today's readings: green on launched and acquired products (+18%), on leverage (2.7 times, at the edge) and on the obesity timeline. Normalized free cash flow reads yellow for 2025 ($10.38 billion) and green on the trailing twelve months ($12.64 billion), so the full 2026 figure decides it. Dividend coverage is yellow (1.06 times in 2025). Impairments are red today: $4.3 billion in the second quarter of 2026, after $4.4 billion in the fourth quarter of 2025. The next review point is the third-quarter report on November 3, 2026.

The three most important thesis breakers

1. Normalized free cash flow falls below $9.5 billion in 2027, when Ibrance and Xtandi lose exclusivity, because the launches do not keep pace.
2. The monthly obesity injection fails in Phase 3, or its approval slips beyond 2029.
3. Dividend coverage stays below 1.0 times for two years or leverage rises above 3.2 times, which would force a choice between the dividend and the balance sheet.

Stress test and independent check

I recomputed the normalized free cash flow, all three methods, the triangulation, both sensitivity tables, the reverse valuation, the coverage ratios and the margin of safety in a separate script. Reported inputs were checked against the second-quarter release and 10-Q, the 2025 10-K, the earnings calls and the market close.

Only the most generous combination of every favorable assumption reaches the price, and even that leaves 2.7% of upside. Every single change on its own lands below $28.40. That is why the verdict is a hold and not a buy, and also why it is not a reduce: the price is a fair estimate of the optimistic case, not a mistake.

The strongest counter-thesis, for the bulls: Pfizer trades at under 10 times earnings while the repatriation tax ends, COVID working capital unwinds, Vyndamax runs to 2031 and $9.7 billion of savings arrive. If normalized free cash flow is really $13 billion rather than $11 billion, the stock is cheap. The response is arithmetic. At my Base multiple of 12 times, $13 billion of free cash flow plus the obesity value is worth $28.22 a share, about today's price. The bull case needs higher cash and a higher multiple at the same time.

Main data limits: the $14 billion to $15 billion size of the patent cliff comes from a third-party account of the first-quarter call, not a transcript I read. Revenue and free cash flow paths, the obesity value and the Bear and Bull EPS are my estimates. The 2027 consensus EPS is a third-party summary of quarterly estimates. Net debt counts cash and short-term investments only, which is slightly conservative because long-term investments are excluded. I could not verify Pfizer's historical valuation multiples, so that part of the valuation score is left out.

Final verdict: hold at $28.40

Pfizer is a real business with real cash, but the cash is about half the size of the earnings the stock is usually judged on, and nearly all of it already goes to the dividend. At $28.40 the market pays for the patent cliff to be bridged and for growth to return in 2029. That may well happen. It is simply already in the price.

Verdict: HOLD at $28.40, watchlist for new money. Triangulated Base value $25.70, downside 9.5%, Confidence C (14/25), required margin of safety 45%, maximum buy price $14.14.

The main risk to this verdict is that working capital and the end of the tax payments lift free cash flow to $13 billion or more and the obesity program reads out well, which would move the value toward my Bull case of $34.02. Until then, the 6% yield is not a discount on the shares. It is the rent you collect while waiting to find out whether the new drugs arrive before Eliquis leaves.

Sources

Primary sources include Pfizer's second-quarter 2026 earnings release and Form 10-Q for the quarter ended June 28, 2026, the 2025 Form 10-K, the fourth-quarter 2025 and first- and second-quarter 2026 earnings call transcripts, a September 14, 2026 conference transcript, and Pfizer's announcements of the fourth-quarter 2026 dividend, the Vyndamax settlements and the Tukysa approval, accessed through Bigdata.com. The October 12, 2026 close of $28.40, the price history and the cash flow history come from StockAnalysis (cash flow statement). Quarterly consensus estimates are third-party figures and are labeled as estimates.

The reference market price is the October 12, 2026 regular session close at 4:00 PM EDT. Balance sheet figures are as of June 28, 2026. The share count is the 5.74 billion diluted shares in Pfizer's 2026 guidance. Normalized free cash flow, revenue and cash flow paths, the obesity value, scenario values and robustness tests are analytical estimates, not company guidance.